Abbott India Ltd Stock Price Today (NSE: ABBOTINDIA)
Fundamental Score
Abbott India Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Abbott India Ltd share price today is ₹26035.00, up +0.83% on NSE/BSE as of 5 June 2026. Abbott India Ltd (ABBOTINDIA) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹63.36K (Cr). The 52-week high for ABBOTINDIA share price is ₹37000.00 and the 52-week low is ₹25150.00. At a P/E ratio of 41.99x, ABBOTINDIA is currently trading above its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 35.68% and a debt-to-equity ratio of 0.05.
Abbott India Ltd Share Price Chart — NSE/BSE Historical Performance
Abbott India Ltd share price chart: 8.53% return over the past month. 52-week high ₹37000.00, 52-week low ₹25150.00.
Abbott India Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹26725.00 | ₹26745.00 | ₹26265.00 | ₹26295.00 | 6.59K (Cr) | |
| ₹27095.00 | ₹27175.00 | ₹26570.00 | ₹26840.00 | 7.11K (Cr) | |
| ₹27735.00 | ₹27845.00 | ₹26630.00 | ₹26855.00 | 10.98K (Cr) | |
| ₹27735.00 | ₹27735.00 | ₹27735.00 | ₹27735.00 | 0.00 (Cr) | |
| ₹27800.00 | ₹27825.00 | ₹27455.00 | ₹27735.00 | 5.17K (Cr) | |
| ₹27865.00 | ₹27880.00 | ₹27500.00 | ₹27610.00 | 14.42K (Cr) | |
| ₹27885.00 | ₹27965.00 | ₹27400.00 | ₹27705.00 | 11.20K (Cr) | |
| ₹27745.00 | ₹27985.00 | ₹27185.00 | ₹27830.00 | 8.81K (Cr) | |
| ₹27495.00 | ₹27880.00 | ₹27495.00 | ₹27715.00 | 6.96K (Cr) | |
| ₹27845.00 | ₹27950.00 | ₹27320.00 | ₹27445.00 | 5.28K (Cr) |
Abbott India Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹27095.00 | ₹27175.00 | ₹26265.00 | ₹26295.00 | -2.95% | |
| ₹25480.00 | ₹28280.00 | ₹25175.00 | ₹26855.00 | +5.40% | |
| ₹26415.00 | ₹26550.00 | ₹25150.00 | ₹25435.00 | -3.71% | |
| ₹26025.00 | ₹28490.00 | ₹25350.00 | ₹25915.00 | -0.42% | |
| ₹27470.00 | ₹27910.00 | ₹26075.00 | ₹26530.00 | -3.42% | |
| ₹28860.00 | ₹28990.00 | ₹26430.00 | ₹27565.00 | -4.49% | |
| ₹30200.00 | ₹30200.00 | ₹27430.00 | ₹29025.00 | -3.89% | |
| ₹29000.00 | ₹30655.00 | ₹28600.00 | ₹30075.00 | +3.71% | |
| ₹29500.00 | ₹30560.00 | ₹28900.00 | ₹28995.00 | -1.71% | |
| ₹31650.00 | ₹32775.00 | ₹29060.00 | ₹29290.00 | -7.46% | |
| ₹34550.00 | ₹34815.00 | ₹31175.00 | ₹31480.00 | -8.89% | |
| ₹35675.00 | ₹35955.00 | ₹32565.00 | ₹34405.00 | -3.56% |
AI Research Briefing
Powered by Gemini · 2026-04-17
Abbott India's oncology bet is a high-stakes game with stretched valuation; integration risks loom.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Abbott India's shares hit a 52-week low of on March 24, 2026. Abbott India halted stock trading on April 1, 2026, ahead of FY26 results. Abbott completed its acquisition of Exact Sciences on March 23, 2026, for $21 billion, establishing itself in the oncology diagnostics market. Abbott's Q1 2026 sales increased 7.8%. They project full-year comparable sales growth of 6.5% to 7.5% and adjusted diluted EPS of $5.38 to $5.58, including a $0.20 dilution related to the Exact Sciences acquisition.
CORE STORY (THE REAL GAME)
Abbott India is evolving from a pure-play pharma company to a healthcare giant with a strong oncology diagnostics presence, driven by the Exact Sciences acquisition. The market is watching to see if they can successfully integrate and scale the acquired business while maintaining profitability.
- Exact Sciences acquisition completed on March 23, 2026
- Q1 2026 sales increased 7.8%
- Full-year comparable sales growth projected at 6.5% to 7.5%
- Successful integration of Exact Sciences
- Positive clinical trial results for new products
- Faster-than-expected growth in oncology diagnostics
- High P/B ratio of 13.5 indicates premium valuation
- Exact Sciences acquisition brings $0.20 EPS dilution
- Subdued inventory and debtors turnover ratios
DII decreased holdings by 0.07%
Indian pharma sector benefits from government initiatives like Biopharma SHAKTI and PLI schemes, but faces increasing competition and regulatory scrutiny.
Yes, Free Cash Flow 5Y: ₹4591.58 Cr
Abbott's future hinges on its ability to successfully integrate Exact Sciences and capitalize on the growing oncology diagnostics market. Expect volatility as the market assesses the long-term impact of the acquisition.
Primary Thesis Risk
Failed integration of Exact Sciences will crater the stock.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Abbott India Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Abbott India Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ABBOTINDIA across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (35.68%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (46.25%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (23.71%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Excellent EPS Growth (18.98% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (18.98% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.05)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (103.78x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹4591.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (74.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Premium Valuation Risk (P/E: 41.99x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Limited Institutional Interest (FII+DII: 9.27%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
Abbott India Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Abbott India Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Abbott India LtdAbbott India Lt...Selected✓ ABBOTINDIA • 500488 | 65/100 | ₹26035.00₹26035 | ₹63358.16₹63358.16 | 41.99Average 42.0 Average | 35.68%Excellent 35.68% Excellent | 46.25%Excellent 46.25% Excellent | 0.05Excellent 0.1 Excellent | 18.98%Excellent 18.98% Excellent | 9.38%Good 9.38% Good | 1.59% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1882.30₹1882 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4460.10₹4460 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1335.20₹1335 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2287.40₹2287 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2492.60₹2493 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Abbott India Ltd PE Ratio History
Historical price-to-earnings ratio for ABBOTINDIA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹665.62 | ₹29025.00 | 43.6x |
| FY 2024 | ₹565.28 | ₹29741.00 | 52.6x |
| FY 2023 | ₹446.78 | ₹22851.25 | 51.1x |
| FY 2022 | ₹375.86 | ₹21367.20 | 56.8x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Abbott India Ltd Dividend History
Annual cash dividends paid by ABBOTINDIA — dividend yield 1.59%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹871.22 Cr |
| FY 2024 | ₹690.60 Cr |
| FY 2023 | ₹584.36 Cr |
| FY 2022 | ₹584.36 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Abbott India Ltd Quarterly Performance
Latest quarterly metrics for ABBOTINDIA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
7.62%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
15.80%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
9.38%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
18.98%
Compounded annual net profit growth over 5 years
Abbott India Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for ABBOTINDIA — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Abbott India Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Abbott India Ltd (ABBOTINDIA) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Abbott India Ltd
About ABBOTINDIA (Abbott India Ltd)
Abbott India Ltd is a prominent player in the Indian pharmaceutical landscape, dedicated to delivering a diverse portfolio of healthcare solutions. With a legacy rooted in innovati...on and patient-centricity, the company focuses on addressing critical health needs across various therapeutic areas. Abbott India's commitment extends to providing high-quality medicines and solutions accessible to a broad spectrum of the Indian population. Through strategic collaborations and a robust research and development pipeline, the company continues to enhance its offerings, striving to improve the lives of individuals and contribute to a healthier nation. Its presence resonates with trust and reliability, solidifying its position as a leading pharmaceutical organization in India. The company's pharmaceutical products cater to a wide range of medical specialties, encompassing areas like gastroenterology, women's health, metabolic disorders, and central nervous system conditions. It offers solutions for conditions like insomnia, vitamin D deficiency, and pre-term labor, and chronic pain management. Abbott India also manufactures and sells vaccines to prevent infections and protect populations. This diverse portfolio reflects a comprehensive approach to healthcare, addressing both prevalent and emerging medical challenges in the country. By focusing on innovation and quality, Abbott India ensures that patients have access to effective and reliable treatments, improving overall health outcomes and well-being. Beyond its core therapeutic areas, Abbott India extends its pharmaceutical reach into segments like anti-infectives, cardio-diabetology, gastrointestinal and hepatology, hormones, neuropsychiatry, respiratory illnesses, and neuroscience. In addition, Abbott India offers a range of products targeting hepatic conditions, metabolic disorders, and gennext healthcare needs, solidifying its commitment to holistic well-being. Furthermore, the company provides consumer healthcare products designed to promote preventative care and healthy living. Through this diverse range of solutions, Abbott India demonstrates its dedication to addressing a wide spectrum of health requirements, reinforcing its role as a trusted partner in India's healthcare ecosystem.
Company Details
Key Leadership
Corporate Events
Latest News
ABBOTINDIA Share Price: Frequently Asked Questions
What is the current share price of Abbott India Ltd?
Abbott India Ltd (ABBOTINDIA) trades at ₹26035.00 on NSE and BSE. Market cap ₹63.36K (Cr). Educational data only.
What is the P/E ratio of Abbott India Ltd?
Abbott India Ltd has a P/E of 41.99x vs industry average 31.77x.
What is the Bull Run score for Abbott India Ltd?
Abbott India Ltd has a Bull Run score of 65/100 based on 25+ financial parameters.
Does Abbott India Ltd pay dividends?
Abbott India Ltd has a dividend yield of 1.59%. Past dividends don't guarantee future payments.
What is the ROE of Abbott India Ltd?
Abbott India Ltd has ROE of 35.68%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Abbott India Ltd?
Abbott India Ltd has debt-to-equity of 0.05.
Is Abbott India Ltd a good investment?
Bull Run gives Abbott India Ltd a score of 65/100. This is not investment advice — consult a SEBI-registered advisor.